Riik: Kanada
keel: inglise
Allikas: Health Canada
PROPAFENONE HYDROCHLORIDE
PHARMASCIENCE INC
C01BC03
PROPAFENONE
150MG
TABLET
PROPAFENONE HYDROCHLORIDE 150MG
ORAL
100
Prescription
CLASS IC ANTIARRYTHMICS
Active ingredient group (AIG) number: 0116258001; AHFS:
CANCELLED POST MARKET
2017-05-24
PRODUCT MONOGRAPH PR PMS-PROPAFENONE Propafenone hydrochloride 150 mg and 300 mg Film Coated Tablets Professed Standard ANTIARRHYTHMIC AGENT PHARMASCIENCE INC. 6111 Royalmount Avenue, Suite 100 Montréal, CANADA H4P 2T4 DATE OF REVISION: OCTOBER 5, 2016 CONTROL NO. 198300 _ _ _ _ _Page 2_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS ................................................................................. 5 ADVERSE REACTIONS ................................................................................................. 10 DRUG INTERACTIONS ................................................................................................. 13 DOSAGE AND ADMINISTRATION ............................................................................. 16 OVERDOSAGE ............................................................................................................... 17 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 18 STORAGE AND STABILITY ......................................................................................... 20 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 20 PART II: SCIENTIFIC INFORMATION ............................................................................... 22 PHARMACEUTICAL INFORMATION ......................................................................... 22 CLINICAL TRIALS ......................................................................................................... 23 DETAILED PHARMACOLOGY ................................................................. Lugege kogu dokumenti